[go: up one dir, main page]

SV2008002825A - Formulaciones de acetato de bazedoxifeno - Google Patents

Formulaciones de acetato de bazedoxifeno

Info

Publication number
SV2008002825A
SV2008002825A SV2008002825A SV2008002825A SV2008002825A SV 2008002825 A SV2008002825 A SV 2008002825A SV 2008002825 A SV2008002825 A SV 2008002825A SV 2008002825 A SV2008002825 A SV 2008002825A SV 2008002825 A SV2008002825 A SV 2008002825A
Authority
SV
El Salvador
Prior art keywords
acetate formulations
bazedoxifen acetate
bazedoxifen
formulations
preparations
Prior art date
Application number
SV2008002825A
Other languages
English (en)
Inventor
Syed M Shah
Christopher R Diorio
Eric C Ehrnsperger
Kadum A Ali
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2008002825(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2008002825A publication Critical patent/SV2008002825A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A FORMULACIONES DE ACETATO DE BAZEDOXIFENO QUE TIENEN UNA CONVERSIÓN POLIMÓRFICA REDUCIDA, A COMPOSICIONES QUE LAS CONTIENEN, A SUS PREPARACIONES Y SUS USOS
SV2008002825A 2005-08-24 2008-02-22 Formulaciones de acetato de bazedoxifeno SV2008002825A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71076105P 2005-08-24 2005-08-24

Publications (1)

Publication Number Publication Date
SV2008002825A true SV2008002825A (es) 2008-06-30

Family

ID=37772333

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2008002825A SV2008002825A (es) 2005-08-24 2008-02-22 Formulaciones de acetato de bazedoxifeno

Country Status (21)

Country Link
US (1) US7771744B2 (es)
EP (1) EP1919456A2 (es)
JP (2) JP2009506053A (es)
KR (2) KR101584674B1 (es)
CN (1) CN101304731B (es)
AR (1) AR056471A1 (es)
AU (1) AU2006283121A1 (es)
BR (1) BRPI0615341A2 (es)
CA (1) CA2620174A1 (es)
CR (1) CR9746A (es)
EC (1) ECSP088214A (es)
GT (1) GT200600383A (es)
IL (2) IL189648A (es)
MX (1) MX2008002484A (es)
NO (1) NO20080991L (es)
PE (1) PE20070425A1 (es)
RU (1) RU2417084C2 (es)
SV (1) SV2008002825A (es)
TW (1) TW200738281A (es)
WO (1) WO2007024961A2 (es)
ZA (1) ZA200801742B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1732528A1 (en) * 2004-04-08 2006-12-20 Wyeth Bazedoxifene acetate solid dispersion formulations
AR056471A1 (es) * 2005-08-24 2007-10-10 Wyeth Corp Formulaciones de acetato de bazedoxifeno
NZ572106A (en) * 2006-03-31 2010-12-24 Rubicon Res Private Ltd Directly compressible composite for orally disintegrating tablets
US20100092564A1 (en) * 2006-12-21 2010-04-15 Jae Han Park Composition of and Method for Preparing Orally Disintegrating Tablets
WO2009102771A1 (en) * 2008-02-11 2009-08-20 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
JP6093707B2 (ja) * 2010-11-30 2017-03-08 ウィスタ ラボラトリーズ リミテッド 化合物製剤
EP2471770A1 (en) * 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
WO2013182169A1 (en) * 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
CN103877581B (zh) * 2014-03-24 2016-03-02 江苏知原药业有限公司 一种性能优异的乙酸巴多昔芬缓释制剂
WO2018182205A1 (ko) * 2017-03-30 2018-10-04 한미약품 주식회사 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
CN112754999A (zh) * 2021-01-23 2021-05-07 郑州泰丰制药有限公司 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法
CN113368075A (zh) * 2021-06-29 2021-09-10 郑州泰丰制药有限公司 一种醋酸巴多昔芬片及其制备方法
EP4392030A4 (en) * 2021-08-23 2025-07-16 Oxygen Biotech LLC TREATMENT OF COVID-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
EP0833642B1 (en) * 1995-06-22 2002-04-10 Akzo Nobel N.V. Compressed dry-granulation desogestrel tablets
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
EP1531807A4 (en) * 2002-06-13 2007-10-31 Wyeth Corp Bazedoxifene TREATMENT SCHEMES
TW200526206A (en) * 2004-01-13 2005-08-16 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
PE20060676A1 (es) * 2004-04-07 2006-07-24 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno
UA85703C2 (en) * 2004-04-07 2009-02-25 Уайет Crystalline polymorph of bazedoxifene acetate
CA2561296A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of bazedoxifene acetate
EP1732528A1 (en) * 2004-04-08 2006-12-20 Wyeth Bazedoxifene acetate solid dispersion formulations
AR056471A1 (es) * 2005-08-24 2007-10-10 Wyeth Corp Formulaciones de acetato de bazedoxifeno

Also Published As

Publication number Publication date
US7771744B2 (en) 2010-08-10
RU2417084C2 (ru) 2011-04-27
JP2013209419A (ja) 2013-10-10
ECSP088214A (es) 2008-03-26
CN101304731A (zh) 2008-11-12
IL233392A (en) 2017-02-28
KR20140088917A (ko) 2014-07-11
WO2007024961A3 (en) 2007-06-28
TW200738281A (en) 2007-10-16
CR9746A (es) 2008-08-21
KR101584674B1 (ko) 2016-01-13
EP1919456A2 (en) 2008-05-14
GT200600383A (es) 2007-03-29
US20070048374A1 (en) 2007-03-01
PE20070425A1 (es) 2007-07-02
IL189648A (en) 2014-07-31
IL233392A0 (en) 2014-08-31
CA2620174A1 (en) 2007-03-01
ZA200801742B (en) 2010-10-27
JP2009506053A (ja) 2009-02-12
AU2006283121A1 (en) 2007-03-01
AR056471A1 (es) 2007-10-10
MX2008002484A (es) 2008-04-07
NO20080991L (no) 2008-05-15
BRPI0615341A2 (pt) 2011-05-17
WO2007024961A2 (en) 2007-03-01
RU2008107580A (ru) 2009-09-27
KR20080043853A (ko) 2008-05-19
IL189648A0 (en) 2008-08-07
CN101304731B (zh) 2012-06-20

Similar Documents

Publication Publication Date Title
SV2008002825A (es) Formulaciones de acetato de bazedoxifeno
DK3692983T3 (da) Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
EP1879659A4 (en) REIZARING COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
AR059978A1 (es) Composiciones farmaceuticas
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CO6551677A2 (es) Composiciones orales que contiene extractos de zingiber officinale y métodos relacionados
ECSP10010433A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
CO6541602A2 (es) Composiciones orales que contienen extractos de zizyphus joazeiro y método relacionados
HRP20160661T1 (hr) Fotozaštitni pripravci koji sadrže sinergijsku kombinaciju aktivnih tvari kreme za sunčanje
PL2173321T3 (pl) Tabletkowane formulacje lipofilowych składników zdrowotnych
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
BRPI0819449A2 (pt) Composições cosméticas de multietapas
EP2001400A4 (en) ORAL FORMULATIONS OF GLYCYL-2-METHYLPROLYL-GLUTAMATE
CY1115673T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν 2-οξο-1-πυρρολιδινο παραγωγα
CO6541604A2 (es) Composiciones orales que contienen extractos de myristica fragrans y métodos relacionados
EP2185112A4 (en) Stabilized therapeutic compositions and formulations
CR8615A (es) Polimorfo cristalino de un acetato de bazedoxifeno
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
DK3348258T3 (da) Orale og injicerbare formuleringer af tetracyclinforbindelser
MX2009007764A (es) Formulacion de nevirapina de liberacion prolongada.
GT200600413A (es) Formulacion solida de mezclas fungicidas
PA8629301A1 (es) Formulaciones de acetato de bezedoxifeno
NO20071485L (no) Kjemiske substanser.
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação

Legal Events

Date Code Title Description
FC Refusal